Kura Oncology to Participate in Upcoming Investor Conference
Kura Oncology (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the UBS Virtual Oncology Day. The management presentation is scheduled for October 1, 2025, at 2:30 p.m. ET.
Investors can access the live audio webcast through the Investors section of Kura's website, with a replay available after the event.
Kura Oncology (NASDAQ:KURA), azienda biopharma in fase clinica specializzata in medicine di precisione per il trattamento del cancro, ha annunciato la sua prossima partecipazione all'UBS Virtual Oncology Day. La presentazione della direzione è prevista per 1 ottobre 2025 alle ore 14:30 ET.
Gli investitori possono accedere alla trasmissione audio in diretta tramite la sezione Investitori del sito di Kura, con una replica disponibile dopo l'evento.
Kura Oncology (NASDAQ:KURA), empresa biofarmacéutica en fase clínica centrada en fármacos de precisión para el tratamiento del cáncer, ha anunciado su próxima participación en el UBS Virtual Oncology Day. La presentación de la dirección está programada para el 1 de octubre de 2025 a las 2:30 p.m. hora ET.
Los inversores pueden acceder a la transmisión de audio en vivo a través de la sección de Inversores en el sitio web de Kura, con una repetición disponible tras el evento.
Kura Oncology(NASDAQ:KURA)는 암 치료를 위한 정밀 의약품에 초점을 둔 임상 단계의 생명공학 제약회사로서 다가오는 UBS Virtual Oncology Day 참가를 발표했습니다. 경영진 발표는 2025년 10월 1일 동부 표준시 오후 2시 30분에 예정되어 있습니다.
투자자들은 Kura 웹사이트의 Investors 섹션에서 라이브 오디오 생방송에 접속할 수 있으며, 이벤트 종료 후 재방송이 제공됩니다.
Kura Oncology (NASDAQ:KURA), une société biopharmaceutique en phase clinique axée sur les médicaments de précision pour le traitement du cancer, a annoncé sa prochaine participation à l'UBS Virtual Oncology Day. La présentation de la direction est prévue le 1er octobre 2025 à 14h30, heure de l’Est.
Les investisseurs peuvent accéder à la diffusion audio en direct via la section Investisseurs du site Web de Kura, avec une rediffusion disponible après l’événement.
Kura Oncology (NASDAQ:KURA), ein klinisch fases biopharmazeutisches Unternehmen, das sich auf Präzisionsmedikamente zur Krebsbehandlung konzentriert, hat seine bevorstehende Teilnahme am UBS Virtual Oncology Day bekannt gegeben. Die Management-Präsentation ist vorgesehen für 1. Oktober 2025 um 14:30 Uhr ET.
Investoren können den Live-Audio-Webcast im Bereich Investoren auf der Kura-Website abrufen; eine Wiederholung ist nach der Veranstaltung verfügbar.
Kura Oncology(NASDAQ:KURA)، شركة أدوية حيوية في المرحلة السريرية تركز على أدوية دقيقة لعلاج السرطان، أعلنت عن مشاركتها المقبلة في UBS Virtual Oncology Day. من المقرر أن تكون عرض الإدارة في 1 أكتوبر 2025 الساعة 2:30 م بتوقيت شرق الولايات المتحدة.
يمكن للمستثمرين الوصول إلى البث الصوتي المباشر من خلال قسم المستثمرون في موقع Kura على الويب، مع وجود إعادة تشغيل متاحة بعد الحدث.
Kura Oncology (NASDAQ:KURA)，一家处于临床阶段的生物制药公司，专注于用于癌症治疗的精准药物，宣布将参加 UBS Virtual Oncology Day。管理层演示定于 2025 年 10 月 1 日，美国东部时间下午 2:30。
投资者可通过 Kura 网站的 Investors 部分收听现场音频直播，活动结束后提供重播。
- None.
- None.
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following investor conference.
UBS Virtual Oncology Day
Wednesday, October 1, 2025
2:30 p.m. ET / 11:30 a.m. PT
A live audio webcast will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with an archived replay available following the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
When is Kura Oncology (KURA) presenting at the UBS Virtual Oncology Day?
How can investors access Kura Oncology's UBS Virtual Oncology Day presentation?
What type of company is Kura Oncology (KURA)?
Will there be a replay available of Kura Oncology's UBS presentation?
